Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?

Abstract titles reveal some of ASCO’s key datasets.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.